Skip to main content

Latest Drugs and Treatment Technology for Chondroplasty (Damaged cartilage)


Chondroplasty is a surgery of damaged cartilage with an aim to reduce friction in joints such as knee joint. 
The recent developments in the chondroplasty treatment includes development of radio frequency chondroplasty which uses radio frequency waves to fill cracks and wedges in the cartilage structure and to stimulate growth.

There is also an increasing trend towards miniaturization of devices. Development of alloys have advanced the shavers and made them more efficient to ensure less trauma to the tissue being treated.


Competitive Analysis:
Key players profiled in the report are –
  • Braun Melsungen AG
  • NuOrtho Surgical Inc.
  • Zimmer Biomet Holdings Inc.
  • Smith & Nephew plc
  • Nebula Inc.
  • Gpcmedical
  • Osiris Therapeutics Inc.
  • Sklar Surgical Instruments
  • Stryker Corporation and others.
Intended Audience
  • Global Chondroplasty treatment manufacturers & suppliers
  • Research and development (R&D) companies
  • Hospitals and clinics
  • Academic institutes and universities

Regional Analysis:

The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new instruments and surgical techniques in the US drives the Chondroplasty Industry. The good reimbursement scenario and the greater awareness in the developed regions drive the market.

Europe is the second largest market in the world due to high income and healthcare penetration.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

Comments

Popular posts from this blog

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibro

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Regional Analysis, Competitive Landscape Forecast to 2023

Idiopathic Pulmonary Fibrosis Treatment is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases. Market Overview The high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment. The Global  Idiopathic Pulmonary Fibrosis Treatment Market  is expected to register a  CAGR of 12.3%  during the forecast period of 2019 to 2025, with a market value of USD 2,237 million in 2018. The global IPF treatment market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in Sept

Chatbots in Healthcare Market Research Report by Top Industry Vendors and Applications Scenario till 2023

Chatbots in Healthcare Market Overview Healthcare chatbots are programs which assist patients with queries. This reduces the burden on the clinical staff and lets them focus on their jobs. Automation of various workflow processes in the healthcare sector is likely to propel the demand for these virtual assistants. The global Chatbots in Healthcare Market is expected to touch USD 316.85 million by 2023 at 21.10% CAGR over the forecast period (2018-2023), as per Market Research Future (MRFR). It stood at USD 100.46 million in 2017. Rise of chronic diseases coupled with lack of medical experts to handle queries are main drivers of the market. For instance, cancer patients used chatbots to gain rapid assistance regarding medication and their adverse effects.  The  Chatbots in Healthcare Market   Free Growth Sample will provide valuable insight with an emphasis on the global market including some of the  major players  such As,  Sensely, Inc. (U.S.), Your.MD (U.K.), Buoy Healt